Cardioprotective medication use in hemodialysis patients

BACKGROUND: Cardiovascular disease is the leading cause of mortality in patients with renal failure, accounting for more than 50% of deaths in end-stage renal disease. Risk factor modification with the use of cardioprotective medications such as angiotensin-converting enzyme inhibitors (ACEIs), beta...

詳細記述

保存先:
書誌詳細
主要な著者: Miller, Lisa M, Hopman, Wilma M, Garland, Jocelyn S, Yeates, Karen E, Pilkey, Rachel M
フォーマット: Artigo
言語:Inglês
出版事項: Pulsus Group Inc 2006
主題:
Clinical Studies
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2560515/
https://ncbi.nlm.nih.gov/pubmed/16835669
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料